us.ryaltris.com
The website, us.ryaltris.com, is intended for users logging in from within the United States.
Please visit ryaltris.com and choose one of our alternate destinations based on where you are logging in from.
FOR US HEALTHCARE PROFESSIONALS ONLY
FOR US AUDIENCES ONLY
The website, us.ryaltris.com, is intended for users logging in from within the United States.
Please visit ryaltris.com and choose one of our alternate destinations based on where you are logging in from.
IMPORTANT SAFETY INFORMATION AND INDICATIONS1
CONTRAINDICATIONS
IMPORTANT SAFETY INFORMATION AND INDICATIONS1
CONTRAINDICATIONS
Patients with known hypersensitivity to any ingredients of RYALTRIS, including mometasone furoate. (4)
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most common adverse reactions (≥1% incidence) are dysgeusia, epistaxis, and nasal discomfort. (6.1)
INDICATIONS
RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
For more information, please see the Full Prescribing Information.
To report an adverse event or product complaint, please contact us at us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.
Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or https://www.fda.gov/medwatch.
RYALTRIS and the RYALTRIS logo are registered trademarks of Glenmark Specialty SA.
Distributed by: Hikma Specialty USA Inc. Columbus, OH 43228
IMPORTANT SAFETY INFORMATION AND INDICATIONS1
IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION AND INDICATIONS1
IMPORTANT SAFETY INFORMATION
RYALTRIS may cause serious side effects, including the following:
Call your healthcare provider or get medical help right away if you have symptoms of any of the serious side effects listed above.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. RYALTRIS and other medicines may affect each other, causing side effects.
Especially tell your healthcare provider if you take:
Before you use RYALTRIS, tell your healthcare provider about all of your medical conditions, including if you:
INDICATIONS
RYALTRIS is a prescription nasal spray that contains 2 medicines, olopatadine hydrochloride, an antihistamine, and mometasone furoate, a corticosteroid. RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
For more information, please see Full Prescribing Information.
To report an adverse event or product complaint, please contact us at us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.
Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or https://www.fda.gov/medwatch.
RYALTRIS and the RYALTRIS logo are registered trademarks of Glenmark Specialty SA.
Distributed by: Hikma Specialty USA Inc. Columbus, OH 43228
Reference